During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
As one of six grantee projects, investigators from Yale, Harvard, and Rice University are partnering with Microsoft to bring forward a combined technique for the early detection of NSCLC.
The companies will use Natera's Signatera circulating tumor DNA assay to assess response to NEO-PV-01, a clinical trial-stage neoantigen cancer vaccine.
The study supports the use of liquid biopsy tests to guide treatment decisions, especially in patients who can't be biopsied, or don't have enough tissue available for standard testing.
The companion diagnostic for Pfizer's Xalkori identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids.
The company's ctDx lung cancer assay identifies a variety of different actionable mutations in the blood of non-small cell lung cancer patients.
The test is a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
Highmark will examine the clinical and economic impact of Biocept's Target Selector liquid biopsy in patients with non-small cell lung cancer.
The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
Results of the study, published in JAMA, highlight ongoing and future challenges in translating the promise of comprehensive genomics into clinical benefit.
The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.
A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.